Boston Bags Assets From GSK and Novartis
The US firm is getting its hands on eight programs from two of the world's leading drug makers, seeing an opportunity in areas such as antibiotics where solutions may be more likely to come from biotech rather than big pharma.
You may also be interested in...
In an interview, CEO Rob Armstrong said the company has created “a lot optionality” for how it can develop the programs it takes on from the big pharma’s portfolio management.
A review of biopharma start-up dealmaking and financing activity from October through December 2018, based on data from Strategic Transactions.
Constantine Chinoporos, Boston Pharmaceuticals’ CBO, talks to Scrip about its deal strategy and how it intends to build its pipeline over the next few years, liberated from the constraints of portfolio management.